PTC Therapeutics names new director
10 June 2022 -

PTC Therapeutics, Inc. (NASDAQ: PTCT), a US-based science-driven, global biopharmaceutical company, announced on Thursday that it has named Alethia Young as its new director.

Young has over 20 years of experience in healthcare and biotech equity research and investing. Presently, she is the chief financial officer of Graphite Bio where she manages the company's finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy. She has served at Cantor Fitzgerald as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies.

Previously, Young has served in senior biotech analyst positions at Credit Suisse and Deutsche Bank. She has held the position of a research policy analyst and president at Marwood Group. She started her career at JP Morgan in the investment banking and asset management divisions. Presently, she serves on the board of directors for BUILD NYC.

Young holds a BA in economics and Spanish from Duke University.